Akero Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-09-04: Study NCT06528314; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2023-12-01: Study NCT06215716; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2023-11-10: Study NCT06161571; Company role Lead sponsor; Phase Phase 3; Status Active not recruiting.
- 2021-07-30: Study NCT05039450; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-09-04 | NCT06528314 A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Lead sponsor | Phase 3 | Recruiting | NASH - Nonalcoholic Steatohepatitis; MASH - Metabolic Dysfunction-Associated Steatohepatitis | 2,150 | 2030-03 |
| 2023-12-01 | NCT06215716 A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis | Lead sponsor | Phase 3 | Recruiting | NASH With Fibrosis; MASH With Fibrosis | 1,650 | 2033-02 |
| 2023-11-10 | NCT06161571 A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Lead sponsor | Phase 3 | Active not recruiting | NASH/MASH; NAFLD/MASLD | 700 | 2026-06-19 |
| 2021-07-30 | NCT05039450 A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) | Lead sponsor | Phase 2 | Completed Results posted | NASH - Nonalcoholic Steatohepatitis | 213 | 2025-08-28 |
| 2021-02-16 | NCT04767529 A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) | Lead sponsor | Phase 2 | Completed Results posted | NASH - Nonalcoholic Steatohepatitis | 128 | 2024-05-02 |
| 2019-05-28 | NCT03976401 A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) | Lead sponsor | Phase 2 | Completed Results posted | NASH - Nonalcoholic Steatohepatitis | 110 | 2022-01-10 |